OncoMatch/Clinical Trials/NCT00412594
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Is NCT00412594 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Rituximab and Cladribine for hairy cell leukemia.
Treatment: Cladribine · Rituximab — This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hairy Cell Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Performance status =< 3
Prior therapy
Cannot have received: investigational agent
No prior investigational agent in the 4 weeks prior to initiation of therapy
Cannot have received: chemotherapy
Prior chemotherapy (last 4 weeks)
Lab requirements
Kidney function
Creatinine less than or equal to 2.0 unless related to the disease
Liver function
Bilirubin less than or equal to 3.0; Transaminases less than or equal 3 x upper limit of normal unless related to the disease
Cardiac function
New York Heart Association classification III or IV heart disease [excluded]
Creatinine less than or equal to 2.0 unless related to the disease; Bilirubin less than or equal to 3.0; Transaminases less than or equal 3 x upper limit of normal unless related to the disease; New York Heart Association classification III or IV heart disease [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify